Comparison of two antiretroviral triple combinations including the protease inhibitor indinavir in children infected with human immunodeficiency virus

Pediatric Infectious Disease Journal

Volumn 17, Issue 6, 1998, Pages 495-499

  Wintergerst, Uwe ^a   Hoffmann, Florian ^a   Sölder, Brigitte ^b   Notheis, Gundula ^a   Petropoulou, Theoni ^a   Eberle, Josef ^a   Gürtler, Lutz ^a   Belohradsky, Bernd H ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Children; Human immunodeficiency virus; Indinavir; Lamivudine; Stavudine; Viral load; Zidovudine

Indexed keywords

INDINAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG INDICATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; NEPHROLITHIASIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS LOAD; VIRUS RESISTANCE; VOMITING;

ADOLESCENT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; INFANT; LAMIVUDINE; MALE; REVERSE TRANSCRIPTASE INHIBITORS; STATISTICS, NONPARAMETRIC; VIRAL LOAD; ZIDOVUDINE;

EID: 0031833173     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199806000-00012     Document Type: Article

References (27)

1. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997;387:188-91.
2. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373: 117-22.
3. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
4. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-70.
5. + lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996;334:426-31.
6. Mofenson LM, Korelitz J, Meyer WA, et al. The relationship between human immundeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent and long-term mortality risk in HIV-1-infected children. J Infect Dis 1997;175:1029-38.
7. Shearer WT, Quinn TC, LaRussa P, et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. N Engl J Med 1997;336:1337-42.
8. De Rossi A, Masiero S, Giaquinto C, et al. Dynamics of viral replication in infants with vertically acquired human immunodeficiency virus type 1 infection. J Clin Invest 1996;97: 323-30.
9. Katzenstein DA, Winters M, Bubp J, et al. Quantitation of human immunodeficiency virus by culture and polymerase chain reaction in response to didanosine after long-term therapy with zidovudine. J Infect Dis 1994;169:416-9.
10. Caesar Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HTV-1 infection: the CAESAR trial. Lancet 1997;349:1413-21.
11. Mc Kinney RE, Maha MA, Connor EM, et al. A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. N Engl J Med 1991;324: 1018-25.
12. Englund JA, Baker CJ, Raskino C, et al. Zidovudine, didanosine, or both as initial treatment for symptomatic HIV-infected children. N Engl J Med 1997;336:1704-12.
13. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996;334:1011-7.
14. Lea AP, Faulds D. Ritonavir. Drugs 1996;52:541-8.
15. Stein D, Drusano G, Steigbigel R, et al. Two year follow-up of patients treated with indinavir 800 mg/8 h. Presented at the Fourth Conference of Retroviruses and Opportunistic Infections, Washington, DC, January 22 to 26, 1997.
16. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
17. Mueller BU, Smith S, Sleasman J, et al. A Phase I/II study of the protease inhibitor indinavir in children with HIV infection. Presented at the Eleventh International Conference on AIDS, Vancouver, July 7 to 12, 1996.
18. Yogev R, Stanley K, Nachman SA, Pelton S, McIntosh K, Winznia A. Virologic efficacy of ZDV+3TC vs. d4T + ritonavir (RTV) vs. ZDV + 3TC + RTV in stable antiretroviral experienced HIV-infected children (Pediatric ACTG Trial 338). Presented at the 37th International Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 28 to October 1, 1997.
19. Rutstein RM, Feingold A, Meislich D, Word B, Rudy B. Protease inhibitor therapy in children with perinatally acquired HIV infection. AIDS 1997;11:F107-11.
20. Melvin AJ, Mohan KM, Arcuino LAM, Edelstein RE, Frenkel LM. Clinical, virologic and immunologic responses of children with advanced human immunodeficiency virus type 1 disease treated with protease inhibitors. Pediatr Infect Dis J 1997; 16:968-74.
21. Centers for Disease Control. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Morbid Mortal Wkly Rep 1994; 43(RR-12):1-10.
22. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less: AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997;337:725-33.
23. De Truchis P, Zucman D, Dupont C, et al. Combination therapy with D4T + 3TC + indinavir (IDV) in nucleosides-experienced HIV-infected patients: an open-label study. Presented at the Fourth Conference of Retroviruses and Opportunistic Infections, Washington, DC, January 22 to 26, 1997.
24. Sölder B, Wintergerst U, Notheis G, Eberle J, Gürtler L, Belohradsky BH. Effect of antiretroviral combination therapy (zidovudine/didanosine or zidovudine/lamivudine) on quantitative plasma human immunodeficiency virus-ribonucleic acid in children and adolescents infected with human immundeficieney virus. J Pediatr 1997;130:293-9.
25. Harris M, Conway B, Montaner JSG, Demasi R, Dawson D, Hill A. Revised therapy including two new drugs is superior to addition of one new drug to a failing antiretroviral regimen. BC Center for excellence in HIV/AIDS, Vancouver, BC, Canada, and the INCAS study group. Presented at the 37th International Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 28 to October 1, 1997.
26. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. JAMA 1997;277:1962-9.
27. Raboud JM, Montaner JS, Raes S, et al. Predictors of duration of plasma viral load suppression. Presented at the 37th International Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 28 to October 1, 1997.